XML 25 R12.htm IDEA: XBRL DOCUMENT
v3.8.0.1

COLLABORATIVE ARRANGEMENTS | 12 Months Ended
--- | ---
Dec. 31, 2017
COLLABORATIVE ARRANGEMENTS |
COLLABORATIVE ARRANGEMENTS | 3. COLLABORATIVE ARRANGEMENTS Revenue from Collaborative Arrangements Net revenue recognized under our GSK Agreement was as follows:
|  | Year Ended December 31, |
(In thousands) |  | 2017 |  | 2016 |  | 2015 |
Royalties from a related party—RELVAR/BREO |  | $ | 198,726 |  | $ | 128,638 |  | $ | 59,188 |
Royalties from a related party—ANORO |  |  | 29,036 |  |  | 17,869 |  |  | 7,699 |
Royalties from a related party—TRELEGY |  |  | 179 |  |  | — |  |  | — |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total royalties from a related party |  |  | 227,941 |  |  | 146,507 |  |  | 66,887 |
Less: amortization of capitalized fees paid to a related party |  |  | (13,823 | ) |  | (13,823 | ) |  | (13,823 | )
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Royalty revenue |  |  | 214,118 |  |  | 132,684 |  |  | 53,064 |
Strategic alliance—MABA program license |  |  | 3,099 |  |  | 885 |  |  | 885 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total net revenue from GSK |  | $ | 217,217 |  | $ | 133,569 |  | $ | 53,949 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
LABA Collaboration As a result of the launch and approval of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $220.0 million during the year ended December 31, 2014. Although we have no further milestone payment obligations to GSK pursuant to the LABA Collaboration Agreement, we continue to have ongoing participation as part of the collaboration, including joint steering and joint project committees that are expected to continue over the life of the agreement. The milestone fees paid to GSK were recognized as capitalized fees paid to a related party, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization expense is recorded as a reduction to the royalties from GSK. We are entitled to receive annual royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion. Sales of single-agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO® ELLIPTA®, royalties are upward tiering and range from 6.5% to 10%. We are also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to TRC in connection with the Spin-Off, including TRELEGY® ELLIPTA®, which royalties are upward tiering and range from 6.5% to 10%.

X
- References No definition available. + Details
Name: | inva_CollaborationArrangementsDisclosureAbstract
Namespace Prefix: | inva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -URI http://asc.fasb.org/topic&trid=5833765 + Details
Name: | us-gaap_CollaborativeArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration